Lantibiotic Compositions for Vancomycin-Resistant Enterococci
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of vancomycin-resistant Enterococci (VRE) strains poses a significant challenge due to their intrinsic resistance to antibiotics, leading to infections and colonization in the gastrointestinal tract and other body sites, with severe complications such as sepsis, meningitis, and pneumonia.
Innovation Solution
Development of novel lantibiotics, including those with specific amino acid sequences and thioether cross-links, formulated in pharmaceutical compositions for administration to patients or food, and produced by recombinant bacteria to inhibit VRE growth and colonization, along with bacterial compositions containing supplementary therapeutic bacteria to enhance efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat VRE infections, then treatment effectiveness is compromised due to intrinsic resistance, but alternative therapies are limited and less effective
Solution Approach 1:
The patent changes the chemical structure parameters of the antimicrobial agent by creating lantibiotics with specific amino acid sequences (including DHA and DHB residues) and thioether cross-link patterns. These structural parameter changes enable the lantibiotics to effectively target VRE while maintaining safety profiles, directly addressing the resistance issue without requiring complete treatment paradigm changes
Solution Approach 2:
The patent utilizes recombinant DNA technology to copy and express lantibiotic genes in host cells (such as E. coli or yeast). This allows for the production of pure, consistent lantibiotic samples that can be standardized and scaled, providing a reliable alternative to conventional antibiotic therapy while maintaining effectiveness against VRE
2Reliability
If new lantibiotics are developed to address VRE resistance, then treatment effectiveness improves, but development complexity and production challenges increase
Solution Approach 1:
The patent employs recombinant DNA technology to copy lantibiotic genes from natural sources into host cells. This allows for standardized production processes where the same genetic blueprint can be replicated across different production batches, reducing variability and simplifying quality control despite the complexity of the biological system
Solution Approach 2:
The patent optimizes production parameters including culture conditions, induction methods, and purification protocols to maximize lantibiotic yield while maintaining product quality. By controlling parameters such as temperature, pH, and induction timing, the system achieves consistent production results that simplify manufacturing and regulatory compliance
3Productivity
If lantibiotics are used to inhibit VRE growth, then bacterial counts decrease significantly, but potential side effects and safety concerns must be managed
Solution Approach 1:
The patent designs lantibiotics with specific structural features (including thioether cross-links between specific amino acid pairs) that enable selective action against VRE while sparing commensal bacteria. This local specificity at the molecular level translates to high productivity in terms of VRE inhibition while minimizing harmful effects on the broader microbiota and host
Solution Approach 2:
The patent incorporates safety evaluation frameworks that continuously monitor lantibiotic performance and safety profiles. Feedback from preclinical and clinical studies is used to optimize dosing regimens and identify patients who may be at higher risk for adverse effects, allowing the system to maximize bacterial growth inhibition while minimizing toxicity through informed clinical decision-making
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lantibiotics effectively inhibit and kill VRE, reducing colonization and infection risks, including a 10-99% decrease in bacterial counts and symptom severity, and provide therapeutic benefits against VRE and other gram-positive bacteria.
Implementation Method 1
Lantibiotics are a group of ribosomally-synthesized peptides that are then post-translationally modified, often by dehydration, to include non-naturally occurring amino acids. Lantibiotics with anti-microbial activity are often referred to as lantibiotics.
Data Source
AI summary
The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.